Key result
COX-2 protein expression was significantly decreased in platelets from ITP patients compared to healthy controls, and its inhibition was shown to impair megakaryopoiesis and thrombopoiesis.
Why the study?
The participation of COX-2 in the maturation of megakaryocytes has been reported but barely studied in primary immune thrombocytopenia.
Does COX-2 inhibition impair megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia?
Case-Control (n=65)
Yes
Does COX-2 inhibition impair megakaryopoiesis and thrombopoiesis in primary immune thrombocytopenia?
Absolute Event Rate: 0.6912% vs 1.003%
p-value: p=0.0065
Decreased COX-2 expression in ITP patients is associated with impaired megakaryopoiesis and thrombopoiesis, suggesting COX-2 plays a vital role in platelet production and survival.
May caution against COX-2 inhibitors in ITP; hypothesis-generating for thrombopoiesis modulation, requires human trials.
BACKGROUND: Cyclooxygenase (COX)-2 is a rate-limiting enzyme in the biosynthesis of prostanoids, which is mostly inducible by inflammatory cytokines. The participation of COX-2 in the maturation of megakaryocytes has been reported but barely studied in primary immune thrombocytopenia (ITP). METHODS: The expressions of COX-2 and Caspase-1, Caspase-3 and Caspase-3 p17 subunit in platelets from ITP patients and healthy controls (HC), and the expressions of COX-2 and CD41 in bone marrow (BM) of ITP patients were measured and analyzed for correlations. The effects of COX-2 inhibitor on megakaryopoiesis and thrombopoiesis were assessed by in vitro culture of Meg01 cells and murine BM-derived megakaryocytes and in vivo experiments of passive ITP mice. RESULTS: The expression of COX-2 was decreased and Caspase-1 and Caspase-3 p17 were increased in platelets from ITP patients compared to HC. In platelets from ITP patients, the COX-2 expression was positively correlated with platelet count and negatively correlated to the expression of Caspase-1. In ITP patients BM, the expression of CD41 was positively correlated with the expression of COX-2. COX-2 inhibitor inhibited the count of megakaryocytes and impaired the maturation and platelet production in Meg01 cells and bone marrow-derived megakaryocytes. COX-2 inhibitor aggravated thrombocytopenia and damaged megakaryopoiesis in ITP murine model. CONCLUSION: COX-2 plays a vital role in the physiologic and pathologic conditions of ITP by intervening the survival of platelets and impairing the megakaryopoiesis and thrombopoiesis of megakaryocytes.
No takes yet. Share an insight, caveat, or question.
Zhuang et al. (2023) conducted a case-control in Primary immune thrombocytopenia (ITP) (n=65). Primary immune thrombocytopenia (ITP) vs. Healthy controls was evaluated on Protein expression of COX-2 in platelets (p=0.0065). COX-2 protein expression was significantly decreased in platelets from ITP patients compared to healthy controls, and its inhibition was shown to impair megakaryopoiesis and thrombopoiesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: